Acute Myeloid Leukaemia (AML), the second most common leukemia in both adults and children, poses significant challenges with low survival rates. Learn how collaboration among stakeholders holds promise for progress in AML management and care.
Since 2019, the global biotech and biopharma industry initiated over 1,000 clinical trials for AML. Take a closer look at these treatments, specifically innovative drugs, ongoing clinical trials, and their potential impact on patient outcomes.
By downloading this report, readers will gain valuable insights on patient enrollment, site selection, and navigating global regulatory landscapes tailored to rare diseases, thus propelling forward Cystic Fibrosis (CF) research and treatment.
In this FAQ, we explore the potential impact on patient outcomes as they relate to innovative drugs and clinical trials for CF. By shedding light on these developments, we aim to provide insights into the evolving landscape of CF management and improving patient care.
Opting to take your clinical trial global by partnering with a CRO in the Asia-Pacific region can help your team recruit patients rapidly, gain access to accelerated regulatory pathways, produce high-quality data accepted by the FDA, and leverage sophisticated research infrastructure.
Through our clinical and regulatory consulting arm, BioDesk, see how we're offering support from clinical regulatory specialists with particular expertise across a variety of activities.
